|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FISH, ALL, Extended Panel
Test Code40050
CPT Codes
88271 (x16), 88275 (x8)
Includes
11q (MLL), 4,10,17, 8q (MYC), 14q (IGH), t(9;22), t(12;21), 19p (E2A), 9p (CDKN2A)
Preferred Specimen
5 mL whole blood collected in a sodium heparin (green-top) tube, or
3 mL bone marrow collected in a sodium heparin (green-top) tube
3 mL bone marrow collected in a sodium heparin (green-top) tube
Minimum Volume
1 mL
Other Acceptable Specimens
Whole blood or bone marrow collected in: Sodium heparin (royal blue-top) or sodium heparin lead-free (tan-top) tube
Instructions
Submit 1 to 3 mL of bone marrow or 3 to 5 mL peripheral blood in a green-top (sodium heparin) vacutainer tube and send at room temperature. Other vacutainer tubes containing sodium heparin are acceptable.
Note: Samples must be received in Chantilly, Monday through Friday a.m. within 24 hours of collection.
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Note: Samples must be received in Chantilly, Monday through Friday a.m. within 24 hours of collection.
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: See instructions
Refrigerated: See instructions
Frozen: See instructions
Refrigerated: See instructions
Frozen: See instructions
Methodology
Fluorescence in situ Hybridization (FISH)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Monday-Sunday Morning, Afternoon
Report available: 7 Days
Report available: 7 Days
Reference Range
See Laboratory Report
Clinical Significance
Prognostic investigation of common cytogenetic changes observed in childhood acute lymphoblastic leukemia. Probes for the rearrangement of: 8q24(MYC),9p21(p16;CDKN2A),19p13.3(E2A;TCF3),t(12;21);TEL(E TV6)/RUNX1(AML1)fusion,11q23(MLL),t(9;22)BCR/ABL1 fusion,14q32(IGH), and numerical abnormalities of chromosomes 4,10 and 17.
